

Mobile App to Improve Patient Compliance

Published date: May 6, 2015

Technology description

Invention Summary

A new technology to enhance patient compliance for tuberculosis (TB) therapy has been developed and is available for licensing opportunities. Mobile-Directly Observed Therapy (mDOT) utilizes a cellular health application that allows health care providers the ability to remind patients to take the appropriate medications while monitoring patient compliance. In addition to TB, this technology could be applied to other conditions ranging from HIV to heart disease.

Value Proposition

Improved patient compliance with TB therapy through patient reminders and visual verification of drug administration, leading to a reduction in the costs associated with treatment failure.

Increased TB cure rates and diminished drug resistance through improved medication compliance. Decreased need for in-person medical appointments, saving both the patient and health care provider time and money

Market Opportunity

The World Health Organization estimates that up to a third of the world's population is infected with TB, resulting in 1.7 million deaths a year. While cure rates with available treatments can be up to 95%, the long duration of these treatments (six months to two years) and associated side effects lower patient compliance. This leads to drug resistant TB that is more difficult and costly to treat (estimated to be 4% of new TB cases). In response, monitoring programs have been developed to encourage patient compliance but are difficult to enforce in rural or developing regions due to the required travel, limited health care resources, etc.

Institution

The University of Utah

Inventors

<u>Savanna Meyers</u> Summer Scholar Surgery <u>Catherine Devries</u> Professor Pediatric Urology Darko Pavlovic Zeljko Pavlovic Stacey Cole Research Fellow Surgery

联系我们



叶先生

电话: 021-65679356 手机: 13414935137 邮箱: yeyingsheng@zf-ym.com